Compass Therapeutics (NASDAQ:CMPX) Stock Price Down 7.6% - Here's What Happened

Key Points

• Shares fell 7.6% mid-day to about $6.03 from a $6.53 close, with ~1.30M shares traded—about 45% below the average session volume.
• Analysts maintain a consensus "Moderate Buy" rating with an average price target of $14.20, reflecting sizable implied upside; recent price targets from firms range roughly $12–$15.
• Compass is a clinical‑stage biotech (market cap ~$1.08B) developing CTX‑471 (PD‑1/PD‑L1 bispecific) and DSP107 (CD47‑SIRPα); it reported EPS of –$0.09 last quarter (beating estimates) and is expected to post –$0.36 for the year, with ~68% institutional ownership.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report)'s stock price traded down 7.6% during mid-day trading on Friday . The stock traded as low as $6.13 and last traded at $6.0320. 1,296,434 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 2,373,411 shares. The stock had previously closed at $6.53.

Analyst Upgrades and Downgrades

CMPX has been the subject of several research reports. Wall Street Zen upgraded shares of Compass Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, February 16th. Guggenheim restated a "buy" rating and set a $12.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, March 24th. Craig Hallum initiated coverage on shares of Compass Therapeutics in a research report on Friday, February 13th. They set a "buy" rating and a $15.00 price objective for the company. Canaccord Genuity Group set a $13.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, February 4th. Finally, Raymond James Financial restated an "outperform" rating on shares of Compass Therapeutics in a research report on Thursday, March 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $14.20.

Compass Therapeutics Price Performance

The company's 50-day simple moving average is $5.69 and its 200-day simple moving average is $5.20. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -13.95 and a beta of 1.49.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. Research analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CMPX. Strs Ohio bought a new position in shares of Compass Therapeutics during the first quarter worth approximately $34,000. Creative Planning bought a new position in shares of Compass Therapeutics during the second quarter worth approximately $30,000. XTX Topco Ltd bought a new position in shares of Compass Therapeutics during the second quarter worth approximately $84,000. Invesco Ltd. increased its holdings in shares of Compass Therapeutics by 58.1% during the second quarter. Invesco Ltd. now owns 58,735 shares of the company's stock worth $153,000 after purchasing an additional 21,578 shares during the period. Finally, Adage Capital Partners GP L.L.C. increased its holdings in shares of Compass Therapeutics by 11.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company's stock worth $11,505,000 after purchasing an additional 449,868 shares during the period. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.